Last quarter (Q2 2022), Sihuan Pharmaceutical Holdings Group's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Sihuan Pharmaceutical Holdings Group's net income was $―. See Sihuan Pharmaceutical Holdings Group’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ ―	$ 3.29B	$ 2.46B	$ 2.88B	$ 2.92B	$ 2.75B
Cost of Revenue	$ ―	$ 842.75M	$ 549.78M	$ 588.99M	$ 538.32M	$ 758.96M
Gross Profit	$ ―	$ 2.45B	$ 1.91B	$ 2.29B	$ 2.38B	$ 1.99B
Operating Expense	$ ―	$ 1.81B	$ 1.47B	$ 938.48M	$ 705.60M	$ 534.60M
Operating Income	$ ―	$ 639.67M	$ 448.87M	$ 1.35B	$ 1.67B	$ 1.45B
Net Non Operating Interest Income Expense	$ ―	$ 44.64M	$ 127.51M	$ 164.99M	$ 158.50M	$ 97.43M
Other Income Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Pretax Income	$ ―	$ 486.05M	$ 765.84M	$ -2.42B	$ 2.01B	$ 1.73B
Tax Provision	$ ―	$ 253.28M	$ 219.04M	$ 290.39M	$ 332.80M	$ 250.17M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ 416.51M	$ 473.38M	$ -2.75B	$ 1.62B	$ 1.45B
Basic EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Basic Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 2.65B	$ 2.02B	$ 1.53B	$ 1.24B	$ 1.29B
Net Income From Continuing And Discontinued Operation	$ ―	$ 416.51M	$ 473.38M	$ -2.75B	$ 1.62B	$ 1.45B
Normalized Income	$ ―	$ 461.59M	$ 395.27M	$ 4.24B	$ 1.49B	$ 1.34B
Interest Expense	$ ―	$ 119.31M	$ 8.22M	$ 4.71M	$ 6.06M	$ 46.00K
EBIT	$ ―	$ 605.36M	$ 774.06M	$ -2.42B	$ 2.02B	$ 1.73B
EBITDA	$ ―	$ 914.73M	$ 1.05B	$ -2.06B	$ 2.33B	$ 2.03B

Currency in USD

Sihuan Pharmaceutical Holdings Group Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing